Skip to main content
      RT @uptoTate: In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effect

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effectiveness outcomes between ETN, ADA, and JAKi monotherapy. #ACR22 @RheumNow https://t.co/e8GA45Rrmd https://t.co/zooGxlTftO
      RT @uptoTate: While myositis in the setting of SLE was found to be around 5% in Abs 1453, it was not associated with mor

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      While myositis in the setting of SLE was found to be around 5% in Abs 1453, it was not associated with mortality. #ACR22 @RheumNow https://t.co/hLLuYoXsCv https://t.co/44XGhbPxzW
      Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more. Here are the RheumNow faculty selections for #ACRbest abstracts today:
      RT @uptoTate: DAVIX is a promising surrogate outcome measure of vascular disease in SSc. Questions around cost and acces

      Dr. Rachel Tate uptoTate

      3 years 10 months ago
      DAVIX is a promising surrogate outcome measure of vascular disease in SSc. Questions around cost and access remain. Abs 1541 #ACR22 @RheumNow https://t.co/KJgtcG5ah8 https://t.co/NsK7b8fQFt
      RT @ericdeinmd: @RheumNow video from #ACR22
      Opioid use in PsA and SpA patients
      Discussing abstract 1012 by @AlexisOgdie

      Eric Dein ericdeinmd

      3 years 10 months ago
      @RheumNow video from #ACR22 Opioid use in PsA and SpA patients Discussing abstract 1012 by @AlexisOgdie https://t.co/fKRog1aIkH
      RT @bella_mehta: Out work showing JIA pts with sharp decline in needing TKAs, however increased TKA utilizations for tum

      Bella Mehta bella_mehta

      3 years 10 months ago
      Out work showing JIA pts with sharp decline in needing TKAs, however increased TKA utilizations for tumors!! We are treating inflammatory arthritis better over timein the pediatric population...Natiowide data over 15 years! #ACR22 @Rheumnow abst# 0843 https://t.co/inw41Y1o9r
      An interesting study presented at ACR22 looked at whether neural networks can distinguish seropositive rheumatoid arthritis (RA+), seronegative RA (RA-), and psoriatic arthritis (PsA) using hand MRI data based on the structural inflammation patterns.
      ACR22 Daily Recap: Saturday Recap
      RT @JulianSegan: One of my personal highlights. History lesson with intersection of medicine. The hilarious @adamjbrown

      Julian Segan JulianSegan

      3 years 10 months ago
      One of my personal highlights. History lesson with intersection of medicine. The hilarious @adamjbrown @RheumNow #ACR22 #rheuminations #factsperminute https://t.co/vDoKLsVfhB
      RT @ericdeinmd: Abst0327 #ACR22 SMART-SLE Monitoring
      Some SLE patients with +dsDNA have persistent positivity, others ha

      Eric Dein ericdeinmd

      3 years 10 months ago
      Abst0327 #ACR22 SMART-SLE Monitoring Some SLE patients with +dsDNA have persistent positivity, others have fluctuations Anti-dsDNA in persistently positive HR 1.56 for flare risk Change (up or down!) in dsDNA more than 2x prior visit for fluctuating patients: HR 1.43 @RheumNow https://t.co/YwDPTYWPLu
      RT @ericdeinmd: Abst0324 #ACR22
      How close are we to measuring Interferon Signature in clinical practice?
      NCounter and Bi

      Eric Dein ericdeinmd

      3 years 10 months ago
      Abst0324 #ACR22 How close are we to measuring Interferon Signature in clinical practice? NCounter and BioFire assays studied - correlated well we each other Genes: IFI27, IFI44L, IFIT1, RSAD2 SLE higher than RA or FMS, but does not correlate with SLE activity @RheumNow https://t.co/izpFtj9Pcd
      ×